118 related articles for article (PubMed ID: 36705466)
1. Cip2a induces arginine biosynthesis and promotes tumor progression in non-small cell lung cancer.
Chen D; Fan S; Wang J; Liang Y; Li P; Lv X; Sun Y; Wang Q; Liu H; Zhang C; Yi Y
Mol Carcinog; 2023 Apr; 62(4):561-572. PubMed ID: 36705466
[TBL] [Abstract][Full Text] [Related]
2. CIP2A is overexpressed in non-small cell lung cancer and correlates with poor prognosis.
Dong QZ; Wang Y; Dong XJ; Li ZX; Tang ZP; Cui QZ; Wang EH
Ann Surg Oncol; 2011 Mar; 18(3):857-65. PubMed ID: 20842459
[TBL] [Abstract][Full Text] [Related]
3. Antihelminthic drug niclosamide inhibits CIP2A and reactivates tumor suppressor protein phosphatase 2A in non-small cell lung cancer cells.
Kim MO; Choe MH; Yoon YN; Ahn J; Yoo M; Jung KY; An S; Hwang SG; Oh JS; Kim JS
Biochem Pharmacol; 2017 Nov; 144():78-89. PubMed ID: 28813646
[TBL] [Abstract][Full Text] [Related]
4. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin.
Wei L; Qu W; Sun J; Wang X; Lv L; Xie L; Song X
Cancer Gene Ther; 2014 May; 21(5):194-9. PubMed ID: 24874844
[TBL] [Abstract][Full Text] [Related]
6. CIP2A regulates cancer metabolism and CREB phosphorylation in non-small cell lung cancer.
Peng B; Lei N; Chai Y; Chan EK; Zhang JY
Mol Biosyst; 2015 Jan; 11(1):105-14. PubMed ID: 25325377
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Feng FF; Cheng P; Sun C; Wang H; Wang W
Chin J Nat Med; 2019 Oct; 17(10):768-777. PubMed ID: 31703757
[TBL] [Abstract][Full Text] [Related]
8. Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A.
Chao TT; Wang CY; Chen YL; Lai CC; Chang FY; Tsai YT; Chao CH; Shiau CW; Huang YC; Yu CJ; Chen KF
Oncotarget; 2015 Feb; 6(4):2164-79. PubMed ID: 25537503
[TBL] [Abstract][Full Text] [Related]
9. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
[TBL] [Abstract][Full Text] [Related]
10. CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer.
Lei N; Peng B; Zhang JY
Oncol Rep; 2014 Oct; 32(4):1689-94. PubMed ID: 25109354
[TBL] [Abstract][Full Text] [Related]
11. CIP2A with survivin protein expressions in human non-small-cell lung cancer correlates with prognosis.
Xu P; Xu XL; Huang Q; Zhang ZH; Zhang YB
Med Oncol; 2012 Sep; 29(3):1643-7. PubMed ID: 21874565
[TBL] [Abstract][Full Text] [Related]
12. Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways.
Xiao X; He Z; Cao W; Cai F; Zhang L; Huang Q; Fan C; Duan C; Wang X; Wang J; Liu Y
Int J Oncol; 2016 Jun; 48(6):2608-18. PubMed ID: 27082429
[TBL] [Abstract][Full Text] [Related]
13. CIP2A overexpression induces autoimmune response and enhances JNK signaling pathway in human lung cancer.
Peng B; Chai Y; Li Y; Liu X; Zhang J
BMC Cancer; 2015 Nov; 15():895. PubMed ID: 26560124
[TBL] [Abstract][Full Text] [Related]
14. CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
Gao F; Wang X; Chen S; Xu T; Wang X; Shen Y; Dong F; Zhong S; Shen Z
Oncol Rep; 2018 Nov; 40(5):2445-2454. PubMed ID: 30106121
[TBL] [Abstract][Full Text] [Related]
15. TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway.
Chao TT; Wang CY; Lai CC; Chen YL; Tsai YT; Chen PT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
J Pharmacol Exp Ther; 2014 Nov; 351(2):352-8. PubMed ID: 25187431
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth.
Liu N; He QM; Chen JW; Li YQ; Xu YF; Ren XY; Sun Y; Mai HQ; Shao JY; Jia WH; Kang TB; Zeng MS; Ma J
Mol Cancer; 2014 May; 13():111. PubMed ID: 24884612
[TBL] [Abstract][Full Text] [Related]
17. CIP2A mediates prostate cancer progression via the c-Myc signaling pathway.
Guo Z; Liu D; Su Z
Tumour Biol; 2015 Jun; 36(6):4777-83. PubMed ID: 25636449
[TBL] [Abstract][Full Text] [Related]
18. CIP2A regulates proliferation and apoptosis of multiple myeloma cells.
Zheng Z; Qiao Z; Chen W; Gong R; Wang Y; Xu L; Ma Y; Zhang L; Lu Y; Jiang B; Li G; Dong C
Mol Med Rep; 2016 Sep; 14(3):2705-9. PubMed ID: 27484817
[TBL] [Abstract][Full Text] [Related]
19. Overexpression and small molecule-triggered downregulation of CIP2A in lung cancer.
Ma L; Wen ZS; Liu Z; Hu Z; Ma J; Chen XQ; Liu YQ; Pu JX; Xiao WL; Sun HD; Zhou GB
PLoS One; 2011; 6(5):e20159. PubMed ID: 21655278
[TBL] [Abstract][Full Text] [Related]
20. p90/CIP2A mediates breast cancer cell proliferation and apoptosis.
Liu X; Peng B; Li Y; Lei N; Li W; Zhang JY
Mol Biol Rep; 2014 Nov; 41(11):7471-8. PubMed ID: 25086622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
